Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ellen L. Weisberg
Ibrutinib Targets Mutant-Egfr Kinase With a Distinct Binding Conformation
Oncotarget
Oncology
Studies of TAK1-centered Polypharmacology With Novel Covalent TAK1 Inhibitors
Bioorganic and Medicinal Chemistry
Organic Chemistry
Molecular Medicine
Molecular Biology
Biochemistry
Clinical Biochemistry
Pharmaceutical Science
Drug Discovery
Related publications
Dual Inhibition of EGFR With Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer With and Without T790M Mutations
Cancer Discovery
Oncology
Glucosylated Epigallocatechin Gallate (EGCG) Derivatives Combined With EGFR Tyrosine Kinase Inhibitor Overcome Resistance in EGFR T790M Mutant Lung Cancer
Biomedical Journal of Scientific & Technical Research
Dual Blockade of EGFR Tyrosine Kinase Using Osimertinib and Afatinib Eradicates EGFR‑mutant Ba/F3 Cells
Oncology Reports
Medicine
Cancer Research
Oncology
A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition
OncoTargets and Therapy
Oncology
Pharmacology
Correction To: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined With Chemotherapy Delay Brain Metastasis in Patients With EGFR‑Mutant Lung Adenocarcinoma
Targeted Oncology
Cancer Research
Oncology
Pharmacology
Volume-Based Growth Tumor Kinetics as a Prognostic Biomarker for Patients With EGFR Mutant Lung Adenocarcinoma Undergoing EGFR Tyrosine Kinase Inhibitor Therapy: A Case Control Study
Cancer Imaging
Nuclear Medicine
Radiology
Ultrasound Technology
Oncology
Radiological
Imaging
Medicine
597 EGFR Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors Have Distinct Effects on the Keratinocyte Innate Immune Response
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
The Abl SH2-kinase Linker Naturally Adopts a Conformation Competent for SH3 Domain Binding
Protein Science
Biochemistry
Medicine
Molecular Biology
Ibrutinib: The First Bruton's Tyrosine Kinase Inhibitor
Prescriber
Pharmacology